Amwell(US:AMWL)2025-11-04 21:13Financial Performance - Total revenue for Q3 2025 was $56.3 million, exceeding previous guidance[7] - Subscription revenue reached $30.9 million, while Amwell Medical Group visit revenue was $21.2 million[7] - Gross margin reported at 52.4%[7] - Revenue for the three months ended September 30, 2025, was $56,286 thousand, a decrease from $61,046 thousand in the same period of 2024, representing a decline of 12.9%[15] - Total costs and operating expenses for the three months ended September 30, 2025, were $85,618 thousand, down from $108,416 thousand in 2024, a reduction of 21.0%[15] - The net loss attributable to American Well Corporation for the three months ended September 30, 2025, was $32,378 thousand, compared to a net loss of $43,464 thousand in 2024, reflecting an improvement of 25.0%[15] - Adjusted EBITDA for the three months ended September 30, 2025, was $(12,669) thousand, an improvement from $(31,013) thousand in the same period of 2024[23] Loss and Cash Flow - Net loss for the quarter was ($31.9) million, an increase from ($19.5) million in Q2 2025[7] - Adjusted EBITDA loss was ($12.7) million, compared to ($4.7) million in the previous quarter[7] - The net cash used in operating activities for the nine months ended September 30, 2025, was $(48,598) thousand, compared to $(113,903) thousand in 2024, indicating a reduction in cash outflow of 57.3%[17] - Cash, cash equivalents, and restricted cash at the end of the period on September 30, 2025, totaled $201,683 thousand, down from $245,442 thousand at the end of September 30, 2024, a decrease of 17.8%[17] Guidance and Projections - Revised 2025 revenue guidance is now between $245 million and $248 million, down from $245 million to $250 million[7] - Q4 2025 revenue is projected to be between $51 million and $54 million[7] - Q4 adjusted EBITDA is expected to range from ($15) million to ($12) million[7] - The company aims to achieve positive cash flow from operations by the end of 2026[5] Operational Metrics - Total visits in Q3 2025 were 1.1 million[7] - Research and development expenses for the three months ended September 30, 2025, were $18,582 thousand, slightly down from $19,797 thousand in 2024, a decrease of 6.1%[15] - Sales and marketing expenses for the three months ended September 30, 2025, were $9,078 thousand, a significant decrease from $16,771 thousand in 2024, representing a decline of 45.8%[15] - The company reported a net gain on divestiture of $2,000 thousand for the three months ended September 30, 2025, compared to no gain in the same period of 2024[15] - The weighted-average common shares outstanding for the three months ended September 30, 2025, were 16,214,711, an increase from 15,135,421 in 2024[15]